The EU Medical Devices Regulation will apply in May 2020. Maurits Lugard and Josefine Sommer of Sidley Austin LLP examine what the changes mean for the medtech industry.
The main objective of the EU Medical Devices Regulation (MDR) is to improve patient safety with stricter rules for the assessment of devices, based on a risk classification system. In addition, the new regulation aims to provide a standard review process for Notified Bodies and the industry. However, the piecemeal implementation and delay of the new rules has left some parties confused as to how to best adapt to the regulations.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
In December 2019, a second corrigendum to the MDR was published, granting much-needed relief for manufacturers of certain low-risk medical devices.
This corrigendum makes several corrections to the MDR and – more importantly – adds a four-year transitional period for certain low-risk medical devices, including certain software, currently classified as Class I, that would be moved into a higher-risk class.
With the new rules due to be in place from May 2020, European Pharmaceutical Review’s Victoria Rees discussed the most recent updates with Maurits Lugard, Partner at Sidley Austin LLP, and Josefine Sommer, Senior Associate at Sidley Austin LLP, to discover their views on how the European Commission (EC) plans to apply the new regulations and reflect on the current status of the implementation of the MDR.
Implementation status of the MDR
To date, only nine Notified Bodies have received accreditation under the MDR to assess the conformity of medical devices. Although the current number of MDR-designated Notified Bodies is not encouraging, said Lugard and Sommer, the EC has indicated that further accreditation announcements are under way. With respect to the very limited availability of Notified Bodies, the industry has been arguing that the new system is not yet ready to handle the large number of medical devices which must be reviewed.
Lugard suggested that the delay of the European database on medical devices (Eudamed) makes it challenging for the industry to know where to focus their resources. This postponement may indeed cause some uncertainty for companies who must continue to prepare for the application of the MDR. For example, the obligations and requirements that relate to Eudamed in Article 87 of the MDR (which contains rules on the reporting of serious incidents and field safety corrective actions) will not apply according to Article 123(3)(d). However, it is unclear to what extent the obligations and requirements not specifically linked to Eudamed will be relevant. This, he said, may cause companies, in particular small- and medium-sized enterprises (SMEs), to become confused about how to comply with the new regulation.
Lugard highlighted that a different approach was taken by the legislator with respect to the application of the EU Clinical Trials Regulation (CTR). Originally due to be effective in October 2018, the application of the CTR will only happen once the relevant EU clinical trials information system has achieved full functionality and been audited. Currently, it is predicted that the CTR will not apply before the beginning of 2022, after a delay of more than three years. Lugard mentioned that this approach has given the pharmaceutical industry greater legal certainty and more time to prepare for a holistic implementation of the new rules set out in the CTR.
…delays relating to… the MDR may have a knock-on effect if companies decide to postpone their preparations”
According to Sommer, in addition to improving patient safety in the EU, “one of the objectives of the MDR was to ensure a level playing field between Notified Bodies and manufacturers.” In particular, Notified Bodies should use the same rules and manufacturers should be subject to the same standards of review. Unfortunately, she said, the current status, in particular the piecemeal implementation, the lack of many key guidance documents and the delay of Eudamed, might jeopardise this goal.
Corrigendum No. 2
While Corrigendum No. 2 made some corrections to the MDR, Lugard and Sommer stated that the most significant change is the introduction of a four-year transitional period for certain low-risk medical devices that are currently classified as Class I, but will be moved into a higher-risk class under the MDR. Medical devices that will benefit from the new transitional period are, for example, certain software, reusable surgical instruments, devices containing nanomaterials and substance-based devices. On the other hand, Class I devices that are not moved into a higher-risk class under the MDR will not benefit from these changes.
Sommer mentioned that the new transitional period will provide the manufacturers of medical devices with the advantage of much-needed time to prepare their technical dossiers and gather sufficient clinical data.
Lugard further commented that Corrigendum No. 2 will mainly effect the current lack of MDR-designated Notified Bodies, which are under pressure at present. MDR-designated Notified Bodies will thus be able to focus on the many higher-risk medical devices that need MDR certification.
New transitional period
Transitional periods generally aim to provide additional time for the industry to comply with new rules. However, grace periods may have some reverse effect, resulting in a lack of urgency and ultimately, some confusion.
Lugard added that the new transitional period presents a potential risk as companies may fall into a false sense of security; businesses may spend time focusing on updates that are prone to change in the future.
…only nine Notified Bodies have received accreditation under the MDR to assess the conformity of medical devices”
Sommer highlighted that the opposite scenario also presents a complication: the periods provided for in the MDR are only applicable if no “significant changes” are made to the devices. Companies falling within the transitional periods may therefore be discouraged from innovating and updating their products to avoid falling within the MDR until the rules are clearer and more Notified Bodies are available. Moreover, the constantly changing expectations could lead to higher costs and uncertainty for manufacturers, making it difficult to predict whether their products will fall within the scope of the MDR. She said that this seems paradoxical, as providing companies with higher predictability as to the classification of their medical devices was a key reason for the current changes to the applicable legislation.
Lugard remarked it is not often, if at all, that a corrigendum is used to implement a significant change leading to a delay in the application of legislation. Moreover, he underlined that the delays relating to the implementation of the MDR may have a knock-on effect if companies decide to postpone their preparations for the application of certain aspects of the new system that might be changed again in the near future. This may jeopardise the importance that management gives to compliance.
The future of the MDR
According to Sommer, the focus of the industry in the short-term future is going to be on the numerous Medical Devices Coordination Group (MDCG) guidance documents that have yet to be published. These will help Notified Bodies and the pharmaceutical industry to implement the MDR. For manufacturers of medical devices, the MDCG guidance documents will help to clarify what Notified Bodies may expect in terms of compliance.
Sommer also said that regulators will need to consider new types of innovative devices, such as medical devices using artificial intelligence (AI), which will potentially require new guidance documents or amendments to the legislation.
Several delays and a lack of new guidance documents have therefore impacted the medical device industry; both Lugard and Sommer suggested that clarifying and publishing this information would aid the pharmaceutical industry in complying with the MDR.
Conclusion
The aim of the MDR is to provide a stable framework for medical devices in the EU, providing a standardised process for Notified Bodies and industry and ensuring elevated levels of health and safety protection for patients. However, according to Lugard and Sommer, we are still yet to fully achieve these aims.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.